Behavioral Health Medication Management Resources

Psychotherapeutic Medication Legislation

Pursuant to statute F.S. 409.912(13): The Agency may not pay for psychotropic medication prescribed for a child in the Medicaid program without the express and informed consent of the child’s parent or legal guardian. The physician shall document the consent in the child’s medical record and provide the pharmacy with a signed attestation of this documentation with the prescription. The express and informed consent or court authorization for a prescription of psychotropic medication for a child in the custody of the Department of Children and Families shall be obtained pursuant to s. 39.407.

Consent Forms

Florida Medicaid Drug Therapy Management Program for Behavioral Health

Florida Pediatric Psychiatry Hotline (1-866-487-9507)

The Florida Pediatric Psychiatry hotline provides pediatricians with telephonic access to board-certified, child psychiatrists for a second medical opinion when prescribing psychotherapeutic medication to children and adolescents with psychiatric needs. This service is primarily related to consultation about medication management. Calls are answered on non-holiday weekdays between 8:30 a.m. and 4:30 p.m. (EST). No registration is required and the service is free.

Florida Clozapine Hotline (727-562-6762)

The Florida Clozapine hotline provides psychiatrists with telephonic access to an adult psychiatrist with significant experience prescribing clozapine to patients with severe mental health diagnoses such as refractory schizophrenia. This service is available Monday through Friday between 8:00 am and 5:00 pm. (EST). No registration is required and the service is free.

Clozapine REMS program at FDA

The clozapine shared Risk Evaluation and Mitigation Strategy (REMS) helps to ensure that the benefits of clozapine outweigh its risks. In order to prescribe and dispense clozapine, prescribers and pharmacies are required to be certified in the Clozapine REMS Program. This new program, started on October 12, 2015, replaces the six registries maintained by individual clozapine manufacturers with a single centralized program.

Substance Abuse and Mental Health Services Administration, SAMHSA  

American Society of Addiction Medicine (ASAM)

Adverse Event Reporting

Consumers and health professionals are encouraged to report problems (adverse reactions) with behavioral health medications to the Food and Drug Administration (FDA). Please click on the link below to access the FDA Safety page and report a problem.